1-20 of 1912 Search Results for

leukemia, aml, multiple myeloma

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal: Blood
Blood (2024) 143 (6): 507–521.
Published: 2024
... myeloid leukemia (AML), which may be addressed without significant risk of severe toxicities while providing sufficient abundance for efficient tumor suppression. One approach to overcome this hurdle is dual targeting by an antibody–T-cell receptor (AbTCR) and a chimeric costimulatory signaling receptor...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood blood.2023023568.
Published: 2024
.... Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424447. 2. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood blood.2023020794.
Published: 2024
... (Table S2). Morphology/Cytochemistry BM morphology is necessary to evaluate the degree of infiltration and to differentiate ALL from mainly from acute myeloid leukemia (AML) and ALL from lymphoblastic lymphoma (LBL). There are no specific cytochemistry reactions to classify ALL. Myeloperoxidase is always...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood blood.2023021979.
Published: 2024
... (AML), allogeneic stem cell transplantation (alloHSCT) and the graft-versus-leukemia effect mediated by donor T cells, offer the best chance of long-term remission. However, the concurrent transfer of alloreactive T cells can lead to graft-versus-host disease that is associated with transplant-related...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood blood.2023023166.
Published: 2024
... in the hematopoietic niche and chronic inflammation due to aberrant secretion of cytokines by immune cells have prominent roles in the pathogenesis and progression of myelodysplastic syndromes (MDS). Progression of MDS to acute myeloid leukemia (AML) is associated with an increased inflammatory signature, which...
Includes: Supplemental data
Journal Articles
Clinical Trials & Observations
Journal: Blood
Blood (2024) 143 (3): 233–242.
Published: 2024
... The estimated overall incidence of mal-HLH has been reported to be ∼1% in patients with hematological malignancies, 16 but as high as 9% in patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy, with infections being the most frequent trigger. 17 In hematological malignancies...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood (2024) 143 (3): 214–223.
Published: 2024
... hematopoiesis, low circulating blood counts, and increased risk of progression to acute myelogenous leukemia (AML). Because clinical outcomes are varied in MDS, prognostication of the disease and individualized management plans are essential to optimize long-term outcomes. Thrombocytopenia in MDS is common...
Journal Articles
Journal: Blood
Blood blood.2023019804.
Published: 2024
... myeloid leukemia (AML) diagnosed at 16 years of age and was treated 54 with intensive chemotherapy without hematopoietic stem cell transplantation (HSCT). She has 55 never relapsed from the disease. The patient weighed 89 kg, had a height of 163 cm, and a 56 body mass index 33.5 kg/m2 versus 49 kg, 158 cm...
Journal Articles
Journal: Blood
Blood (2024) 143 (2): 139–151.
Published: 2024
.... CBER . Issued 26 March 2021. Accessed 10 August 2022. https://www.fda.gov/media/147062/download?attachment . 3. D'Agostino M , Raje N . Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? . Leukemia . 2020 ; 34 ( 1 ): 21 - 34 . 4. Gay F , D'Agostino M...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood blood.2023019706.
Published: 2024
... of lymphoma and myeloid leukemia cell lines. 26 Sonrotoclax exhibited more potent cytotoxic activity than venetoclax across multiple cell 27 lines, such as MV4-11 (acute myeloid leukemia, AML), MAVER-1 (mantle cell lymphoma, 28 MCL), and Toledo (diffuse large B-cell lymphoma, DLBCL) (Figure 2D; supplemental...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood (2024) 143 (1): 42–56.
Published: 2024
... : 100643 . 6. Garand R , Avet-Loiseau H , Accard F , Moreau P , Harousseau JL , Bataille R . t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma . Leukemia . 2003 ; 17 ( 10 ): 2032...
Includes: Supplemental data
Journal Articles
Clinical Trials & Observations
Journal: Blood
Blood blood.2023022993.
Published: 2024
... inhibition of tumor growth in murine xenografts of acute myeloid leukemia (AML), including with TP53 mutated disease, and in T acute lymphoblastic leukemia (ALL) cells.69,70 Bromodomain and extraterminal domain (BET) proteins epigenetically regulate c-Myc transcription and have been exploited as targets...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood (2023) 142 (26): 2247–2257.
Published: 2023
... cytopenic clonal proliferations, and the border between MDS and acute myeloid leukemia (AML). 1-4 Current diagnostic criteria establish a precise level of morphologic dysplasia (10% dysplastic cells) and maturation impairment (20% blasts) that separate MDS from nonneoplastic clonal hematopoiesis and AML...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood (2023) 142 (26): 2282–2295.
Published: 2023
... of the human BM microenvironment, in a variety of physiologic and pathologic states, including metastatic disease and numerous hematologic malignancies, such as myelodysplasia, acute leukemia, myeloma, and other marrow-based myeloid and lymphoid neoplasia. This work was supported by the Department...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood (2023) 142 (26): 2235–2246.
Published: 2023
... mutations associated with acute myeloid leukemia (AML), including mutations in IDH1/2 , FLT3 , and DNMT3A -R882, ultradeep sequencing identified CH with VAF as low as 0.8% in individuals aged < 60 years. 6 Somatic mutations in HSCs that cause CH can be acquired early in life. 38-40...
Journal Articles
Journal: Blood
Blood blood.2023022882.
Published: 2023
... lymphoma (8) Marginal zone & mantle B-cell lymphoma (7) Diffuse Large B-cell Lymphoma (29) B-cell ALL (22) Hodgkin Lymphoma (7) CLL (7) Multiple Myeloma (29) T-cell ALL (15) AML (44) CML (17) Anaplastic Large Cell Lymphoma (10) Breast (62) Pancreas (53) Renal (38) Brain (83) Skin (87) Lung (206) Prostate...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood (2023) 142 (26): 2258–2267.
Published: 2023
... neoplasms characterized by cytopenia and bone marrow (BM) dysplasia caused by underlying clonal hematopoiesis. 1 Because the natural history and prognosis of MDS varies from mild isolated cytopenia to BM failure and a high risk of evolution to acute myeloid leukemia (AML), 2 prognostication and risk...
Journal Articles
Journal: Blood
Blood blood.2023021423.
Published: 2023
.... Pevonedistat plus azacitidine vs 27 azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or 28 low-blast-percentage AML. Blood Adv. 2022;6(17):5132-5145. 29 38. Misawa K, Yasuda H, Matsuda H, et al. Development of Acute Adult T-cell 30 Leukemia Following PD-1 Blockade Therapy for Lung Cancer...
Includes: Supplemental data
Journal Articles
CME Clinical Trials & Observations
Journal: Blood
Blood (2023) 142 (25): 2146–2158.
Published: 2023
... , 18 The most common HMs reported in patients with FPDMM are myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), but B-cell acute lymphoblastic leukemia (B-ALL) and T-cell ALL (T-ALL), hairy-cell leukemia, non-Hodgkin lymphoma, and chronic myelomonocytic leukemia (CMML) have also been...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood (2023) 142 (25): 2175–2191.
Published: 2023
... and characterized by an exchange of serine (S) to asparagine (N) at position 36 has a prevalence of 5% to 7% in different healthy control populations. The prevalence of the GFI1-36N allele is increased (10%-15%) among patients with MDS, acute myeloid leukemia (AML), and multiple myeloma, and the presence...
Includes: Supplemental data